Search

Your search keyword '"Widmark, Anders"' showing total 525 results

Search Constraints

Start Over You searched for: Author "Widmark, Anders" Remove constraint Author: "Widmark, Anders"
525 results on '"Widmark, Anders"'

Search Results

1. Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging

4. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

14. Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328

18. Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET.

19. Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice

20. Suppl FigS3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications

21. Table S3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications

24. Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)

25. IDENTIFICATION OF INTRA-PROSTATIC LESIONS USING PSMA, ACETATE-PET AND MPMRI

26. PROSTATE CANCER RISK CLASSIFICATION FROM MULTIPARAMETRIC MRI AND PET IMAGE DATA EVALUATED BY REGISTERED HISTOPATHOLOGY

27. Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy

29. Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study

30. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

32. Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).

33. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

37. Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C

45. Additional file 1 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

46. Additional file 2 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

47. Additional file 5 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

48. Additional file 3 of A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

49. High Monocyte Count and Expression of S100A9 and S100A12 in Peripheral Blood Mononuclear Cells Are Associated with Poor Outcome in Patients with Metastatic Prostate Cancer

Catalog

Books, media, physical & digital resources